

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

NCT07068191

Status	RECRUITING
Phase	Not Applicable
Sponsor	Phenomen Pharma
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (8)

- Age 18 to 65 years
- Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)
- Hepatomegaly confirmed by ultrasound (e3 cm craniocaudal liver enlargement)
- ALT level between 90-150 U/L
- Steatosis e260 dB/m by FibroScan (CAP)
- ... and 3 more (see full listing online)

Exclusion (7)

- Liver cirrhosis or hepatocellular carcinoma
- Pregnancy or lactation
- Known allergy to any of the study medications or supplement components
- Gallstones or biliary obstruction
- Shrunken liver on imaging
- ... and 2 more (see full listing online)

Locations (1 total)

Tyumen State Medical University, Tyumen, Tyumen Oblast, Russia